Synergistic Effects of Erlotinib and Everolimus on Bronchial Carcinoids and Large-Cell Neuroendocrine Carcinomas with Activated EGFR/AKT/mTOR Pathway

A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results

(2017) V. Papadimitrakopoulou et al.   JOURNAL OF CLINICAL ONCOLOGY

From Targets to Treatments: A Review of Molecular Targets in Pancreatic Neuroendocrine Tumors

(2011) Bertram Wiedenmann et al.   NEUROENDOCRINOLOGY

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study

(2010) E. J. Macaskill et al.   BREAST CANCER RESEARCH AND TREATMENT

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer

(2010) K Schmid et al.   BRITISH JOURNAL OF CANCER

Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

(2010) Kathrin Zitzmann et al.   CANCER LETTERS

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

(2010) A. Tarhini et al.   CLINICAL CANCER RESEARCH

Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids

(2010) Maria Chiara Zatelli et al.   ENDOCRINE-RELATED CANCER

Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung

(2010) Luisella Righi et al.   ENDOCRINE-RELATED CANCER

Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors

(2010) Judith A Gilbert et al.   ENDOCRINE-RELATED CANCER

Reclassification of Neuroendocrine Tumors Improves the Separation of Carcinoids and the Prediction of Survival

(2010) Birgit Guldhammer Skov et al.   Journal of Thoracic Oncology

Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study

(2010) Martin Reck et al.   Journal of Thoracic Oncology

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells

(2010) Yidan Lin et al.   LUNG CANCER

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors

(2010) J. Voortman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy

(2010) Yan Shi et al.   TUMOR BIOLOGY

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study

(2009) Ivette F Emery et al.   BMC CANCER

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

(2009) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells

(2009) B. Herberger et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

(2008) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY

Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line

(2007) Simona Grozinsky-Glasberg et al.   NEUROENDOCRINOLOGY